Friday, July 10, 2026
CVD and Collaborators Launch Study to Better Understand Immune Responses to Lassa Fever
The University of Maryland School of Medicine Center for Vaccine Development and Global Health (CVD), has announced the launch of a research study to understand how Lassa fever survivors fight and overcome Lassa virus infection. The study, titled “Identification and Immunologic Characterization of Adult Lassa Fever Survivors in Nigeria”, is a collaboration between CVD, The Institute of Human Virology Nigeria (IHVN) International Research Center of Excellence (IRCE), and the Abubakar Tafawa Balewa University Teaching Hospital (ATBUTH) in Bauchi State.
Tuesday, June 09, 2026
First-in-Human Clinical Trial Shows Promising Results for New Lassa Fever Vaccine
Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD) reported encouraging results from an early clinical trial that tested a new dual vaccine against Lassa fever and rabies. The study, published today in the journal Nature Medicine, found that the vaccine was safe and induced immune responses against both viruses. There are currently no vaccines against Lassa fever on the market.
Monday, April 20, 2026
Get to Know: Stefan H. Kappe, PhD
Distinguished parasitologist and immunologist Stefan Kappe, PhD, recently became the new Director of the UM School of Medicine’s Center for Vaccine Development and Global Health (CVD) and the Myron M. Levine, MD, DTPH Professor of Vaccinology and Vice Chair for Research in the Department of Pediatrics. During his work at the University of Washington and Seattle Children’s Research Institute, he pioneered the use of genetic engineering to develop live attenuated vaccines against the deadly malaria parasites that sicken hundreds of millions of people and kill up to a million people worldwide each year.
Monday, February 02, 2026
University of Maryland School of Medicine Launches Clinical Trial of Investigative Nasal Spray Medicine to Prevent Illnesses from Respiratory Viruses
Last year, at least one million people in the U.S. were hospitalized for respiratory virus illnesses like the flu or COVID-19, according to the Centers for Disease Control and Prevention. Many of these individuals were at higher risk of getting infections due to living or working around young children who contract more respiratory infections. A new clinical trial led by researchers at the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health (CVD) will test a new experimental intranasal spray designed to boost immune defenses and reduce illness from respiratory viruses.